06.01.18
Johnson & Johnson (J&J) reported a 12.6% rise in sales of $20.0 billion for the first quarter of 2018. Operational sales results increased 8.4% and the positive impact of currency was 4.2%.
J&J said domestic sales increased 6.1% and international sales increased 19.9%, reflecting operational growth of 10.9% and a positive currency impact of 9.0%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.3%, domestic sales increased 1.3% and international sales increased 7.6%.
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by beauty products primarily Neutrogena, Aveeno and Japanese skin care brand Dr. Ci Labo, as well as international analgesics in over-the-counter products, partially offset by the negative impact of domestic baby care products.
J&J said domestic sales increased 6.1% and international sales increased 19.9%, reflecting operational growth of 10.9% and a positive currency impact of 9.0%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.3%, domestic sales increased 1.3% and international sales increased 7.6%.
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by beauty products primarily Neutrogena, Aveeno and Japanese skin care brand Dr. Ci Labo, as well as international analgesics in over-the-counter products, partially offset by the negative impact of domestic baby care products.